...€2 million ($2.1 million) in a financing round from angel investors. SOM Biotech S.L. , Barcelona, Spain Alicia Parker SOM Biotech S.L....

...to treat amyloidosis. SOM declined to disclose additional details. SOM Biotech S.L. , Barcelona, Spain Business: Endocrine/Metabolic Alicia Parker SOM0226 Tolcapone SOM Biotech S.L. Transthyretin...

...NYSE:GSK) ISIS-TTRRx (GSK2998728) TTR antisense inhibitor Ph II/III for FAP mNIS+7 and Norfolk QOL questionnaire SOM Biotech S.L....

...reported. Data were presented at the European Congress on Hereditary ATTR amyloidosis meeting in Paris. SOM Biotech S.L....

...included results from clinical studies of transthyretin amyloid disease therapies from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), SOM Biotech S.L....
...using the GalNAc-conjugate delivery platform. Data in an abstract from a Phase IIa study of SOM Biotech's...